Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–7. Article PubMed CAS Google Scholar Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation...
Experiences of BRCA1/2 Gene Mutation-Positive Women With Cancer in Communicating Genetic Risk to Their RelativesBRCACancerExperiencesFamilyGeneticRisk communicationBackgroundSeven, MemnunShah, Lisa L.Daack-Hirsch, SandraYazici, HulyaUniv Massachusetts Coll Nursing 230 Skinner Hall 651 N Pleasant St ...
Nature GeneticsDuggan DJ, Hedenfalk IA, Chen Y, Bittner M, Borg A, Trent JM. Mi- croarray analysis discriminates BRCA2 mutation-positive from BRCA1 and sporadic breast cancer patient tumour biopsies. Nat Genet 1999; 23 (Supl): 43.
helping me know better how to prevent cancer from EVER threatening my children’s lives like it had already done to mine (see my next post on “Talking to your Kids about the BRCA Gene Mutation”); 2. It also allowed my MOM to knowshe has the BRCA1 gene mutation, and though she’d...
To understand the role of CMTM6 in HER2+ BC, the transcriptomic data of BC were extracted from TCGA-BRCA and stratified into the high or low CMTM6 group, based on the median value of CMTM6 mRNA transcripts. The gene sets involved in tumor-related malignant behaviors and HER2-related signal...
Purpose: As estrogen receptor–positive (ER+) breast cancer in BRCA1 mutation carriers arises at an older age with less aggressive tumor characteristics than ER-negative (ER) BRCA1-mutated breast cancer, it has been suggested that these tumors are "sporadic" and not BRCA1 driven. With the in...
Through an analysis of an online survey of women who tested positive for the BRCA genetic mutation for breast cancer, this research uses a social constructionist and feminist standpoint lens to undersdoi:10.1007/s10897-015-9929-2Hesse-Biber, Sharlene...
To understand the role of CMTM6 in HER2+ BC, the transcriptomic data of BC were extracted from TCGA-BRCA and stratified into the high or low CMTM6 group, based on the median value of CMTM6 mRNA transcripts. The gene sets involved in tumor-related malignant behaviors and HER2-related signal...
The investigational PARP inhibitor veliparib (AbbVie) has shown what investigators say is "promising and encouraging" activity in women with treatment-resistant ovarian cancer who carry aBRCA1orBRCA2mutation. In a phase 2 study of 50 women withBRCAgene mutations, treatment with veliparib resulted in...
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers BACKGROUND: Mutations in the BRCA2 gene are associated with an increased risk of prostate cancer, but it is not known whether they are associated with prog... T Laufey,V Linda,T Tryggvi,... - 《J Natl Cancer Inst》 被引...